metaEvidence - overview


			deaths (OS)
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
versus placebo
	pembrolizumab alone vs. placebo	1	-300 [-573; -26] /10000 18/496 vs. 33/498
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	atezolizumab alone vs. sunitinib	1	-
	atezolizumab plus bevacizumab vs. sunitinib	2	108 [-532; 748] /10000 194/454 vs. 192/461
	avelumab plus axitinib vs. sunitinib	1	-439 [-1022; 144] /10000 109/442 vs. 129/444
	nivolumab plus cabozantinib vs. sunitinib	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	nivolumab plus ipilimumab vs. sunitinib	3	1005 [483; 1528] /10000 429/550 vs. 371/546
	pembrolizumab plus axitinib vs. sunitinib	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	pembrolizumab plus lenvatinib vs. sunitinib	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative
versus sunitinib
	atezolizumab plus bevacizumab vs. sunitinib	1	-
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	atezolizumab alone vs. sunitinib	1	-
	atezolizumab plus bevacizumab vs. sunitinib	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0
	avelumab plus axitinib vs. sunitinib	1	-280 [-1004; 445] /10000 66/270 vs. 79/290
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
	nivolumab alone vs. everolimus	1	-768 [-1449; -86] /10000 183/410 vs. 215/411